ACADIA PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
ACAD$16.50-22.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except per share amounts)
| Years Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenues | |||
| Product sales, net | $726,437 | $517,235 | $484,145 |
| Total revenues | 726,437 | 517,235 | 484,145 |
| Operating expenses | |||
| Cost of product sales | 41,638 | 10,166 | 19,141 |
| Research and development | 351,619 | 361,575 | 239,415 |
| Selling, general and administrative | 406,559 | 369,090 | 396,028 |
| Total operating expenses | 799,816 | 740,831 | 654,584 |
| Loss from operations | (73,379) | (223,596) | (170,439) |
| Interest income, net | 17,234 | 6,610 | 591 |
| Other income | 5,109 | 3,542 | 2,329 |
| Loss before income taxes | (51,036) | (213,444) | (167,519) |
| Income tax expense | 10,250 | 2,531 | 351 |
| Net loss | $(61,286) | $(215,975) | $(167,870) |
| Net loss per common share, basic and diluted | $(0.37) | $(1.34) | $(1.05) |
| Weighted average common shares outstanding, basic and diluted | 163,819 | 161,683 | 160,493 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.